MedWaves Announces Doctors at Hospital of Johann Wolfgang Goethe University in Frankfurt, Germany Perform First Successful Treatment of 'Hot and Cold' Thyroid Nodules With Combination of Its AveCure™ Microwave Ablation System and Radioiodine Unique, non-surgical combination therapy works on both hot and cold thyroid nodules
FRANKFURT, Germany, April 9, 2013 /PRNewswire/ -- Dr. Hudayi Korkusuz, a radiologist at the Department of Nuclear Medicine, has conducted the first combination treatment of microwave ablation and radiotherapy.
Annually in Germany, about 100,000 thyroid operations are performed. In many cases, treatment of nodular goiter has had mixed results from hot and cold thyroid. A hot thyroid nodule is a benign tumor that can be treated with the established radiotherapy. Cold nodes can be malignant and are so far removed surgically. In August 2012, the University Hospital in Frankfurt, Department of Nuclear Medicine (Director: Prof. Dr. Frank Grunwald) performed for the first time a microwave ablation of thyroid nodule on a patient in Europe. Since then, the microwave therapy in Frankfurt has been established. Now the world's first hospital has treated a patient with hot and cold thyroid nodules by the combined use of radioiodine therapy and microwave ablation. Compared to the usual procedures, the new combination therapy for patients is much safer and more comfortable.
Combination of two sound treatment methods
The microwave ablation of the cold node followed by radioactive iodine treatment of the hot node was for the first time this year performed on a 52-year-old patient. For both procedures, no surgery was needed. With microwave ablation, treatment was performed under local anesthesia; a probe is passed through the skin to position the antenna in the node. Its purpose is to apply microwaves directly on the thyroid nodules. The diseased cells are heated by the waves, and the treated thyroid tissue is then metabolized by the body. The thyroid nodule is reduced to smaller size in no time. Using real-time images from an ultrasonic device, the ablation process is monitored and controlled at all times. The duration of treatment depends on size and number of thyroid nodules and normally requires between 10 (ten) and 15 minutes. The microwave treatment is an outpatient procedure usually. Since the treatment is with a thin needle, the cosmetic result is excellent. For the subsequent treatment of the patient's hot node, radioactive iodine in the form of a capsule was administered. The rays cause cell death in the tumor. The node is removed without damaging surrounding tissue. The treatment is very safe and well tolerated. For combination therapy, a hospital stay of a few days is sufficient.
Radioiodine application and microwave ablation are both non-surgical procedures. A big advantage is the fact that the risks of surgery and related anesthesia are completely eliminated. This is especially important for people who have pre-existing conditions, for example, the cardiovascular system problems and thus have an increased risk during surgery.
"The patient stated that a dental visit was more unpleasant than this treatment. We are pleased to be the first clinic to offer our patients this very gentle combination therapy," said Dr. Hudayi Korkusuz, a radiologist at the Department of Nuclear Medicine, who performed the first treatment. The original press-release link:
Microwave ablation system; only system with automatic power and frequency modulation controls based on probe integrated temperature sensor and reflected-power feedback for:
ablations resulting from true microwave energy field without excessive heat build-up to prevent complications.
- Assortment of antennas (1-4cm), control settings: 60-130 degrees C, 0-15minutes and 10-32watts for ablation zone coverage between 1- 5cm.
- Frequency ranging from 902MHz to 928MHz to optimize microwave field tissue penetration depth.
- Efficient energy delivery requires no cooling, no return pads and simple to operate.
- Real-time display of temperature and reflected-power for procedure control.
Contacts: George Leung (Email)
Theodore Ormsby (Email), mobile: 760-807-1000, office: 858-946-0015
This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.
SOURCE MedWaves, Inc.